✦ LIBER ✦

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

✍ Scribed by Tuscano, Joseph M.; Dutia, Mrinal; Chee, Karen; Brunson, Ann; Reed-Pease, Christine; Abedi, Mehrdad; Welborn, Jeanna; O'Donnell, Robert T.

Book ID: 125479346
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 140 KB
Volume: 165
Category: Article
ISSN: 0007-1048
DOI: 10.1111/bjh.12755

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bendamustine Produces Durable Responses

Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma

✍ Bruce D. Cheson; Jonathan W. Friedberg; Brad S. Kahl; Richard H. Van der Jagt; L 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 130 KB

Lenalidomide induced good clinical respo

Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma

✍ Inga Mandac; Slobodanka Ostojic Kolonic 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 600 KB

Pentostatin demonstrates clinical activi

Pentostatin demonstrates clinical activity in patients with relapsed or refractory non-Hodgkin's lymphoma

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Lenalidomide oral monotherapy produces a

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

✍ Thomas M. Habermann; Izidore S. Lossos; Glen Justice; Julie M. Vose; Peter H. Wi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

Lenalidomide in combination with rituxim

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

✍ Michael Wang; Luis Fayad; Nicolaus Wagner-Bartak; Liang Zhang; Fredrick Hagemeis 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 141 KB